Rethinking Remdesivir: Synthesis, Antiviral Activity and Pharmacokinetics of Oral Lipid Prodrugs

Mostrar otras versiones (1)

Remdesivir (RDV, GS-5734) is currently the only FDA-approved antiviral drug for the treatment of SARS CoV-2 infection. The drug is approved for use in adults or children 12-years or older who are hospitalized for the treatment of COVID-19 on the basis of an acceleration of clinical recovery for inpa...

Descripción completa

Detalles Bibliográficos
Autores principales: Schooley, Robert T., Carlin, Aaron F., Beadle, James R., Valiaeva, Nadejda, Zhang, Xing-Quan, Clark, Alex E., McMillan, Rachel E., Leibel, Sandra L., McVicar, Rachael N., Xie, Jialei, Garretson, Aaron F., Smith, Victoria I., Murphy, Joyce, Hostetler, Karl Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457622/
https://www.ncbi.nlm.nih.gov/pubmed/32869033
http://dx.doi.org/10.1101/2020.08.26.269159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457622/
https://www.ncbi.nlm.nih.gov/pubmed/32869033
http://dx.doi.org/10.1101/2020.08.26.269159

Ejemplares similares